At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
dalfampridine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
In Brief
A Phase 4 clinical trial evaluating dalfampridine and Placebo for Non Arteritic Ischemic Optic Neuropathy. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Determine whether dalfampridine (Ampyra) can improve visual function in patients who have had nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Arteritic Ischemic Optic Neuropathy
CountriesUnited States
CollaboratorsAcorda Therapeutics
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedNov 2013
Primary CompletionDec 2015
TodayJul 2026
First PostedNov 4, 2013
Enrollment StartJul 1, 2013
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 12.7 years ago
Interventions
dalfampridinedrug
dalfampridine 10 mgs or placebo twice a day for two weeks, wash out period of two weeks, dalfampridine 10mgs or placebo twice a day for two weeks
Placebodrug
placebo (sugar pill) twice a day for two weeks